Protein C News and Research

RSS

SARS-CoV-2 spike stimulates hyperinflammation via Toll-like receptor 2

A new study, released on the bioRxiv* preprint server, describes the mechanism of inflammation in severe COVID-19, besides revealing a potential new therapeutic target to modulate the severity of COVID-19.

19 Mar 2021

Researchers explore nanotechnology’s potential to deliver synergistic therapeutics for COVID-19

A team of scientists reviewed the nanoencapsulation approaches of synergistic compounds (Lectins, Caffeine, Cocoa, Flavonoids, Quercetin) and the role of nanotechnology in addressing the COVID-19 pandemic.

19 Mar 2021

Researchers characterize regions of DNA that impact MECP2 expression

Researchers at Baylor College of Medicine and the Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital (NRI) have identified and characterized two regions of DNA required for the proper expression of Mecp2/MECP2 in mice and humans.

19 Mar 2021

Side-stream products of malting could be used as human nutrition, indicates study

Malting, the processing of cereal grains into malt, generates rootlets as a side-stream product, which is currently mostly utilized as animal feed.

19 Mar 2021

N-terminal domain antibodies play a key role in COVID immunity

Scientists are learning that a lesser-studied region on the pandemic coronavirus is recognized by COVID-19 infection-fighting antibodies. These antibodies were identified in blood samples from previously infected patients, and were found to potently prevent the virus from infecting cells.

19 Mar 2021

Pancreatic cancer cells use adaptive mechanisms to avoid death by starvation

In new findings published online March 18, 2021 in the journal Cancer Cell, an international team of researchers, led by scientists at University of California San Diego School of Medicine and Moores Cancer Center, describe how pancreatic cancer cells use an alternative method to find necessary nutrients, defying current therapies, to help them grow and spread.

19 Mar 2021

Study shows how ACE2 mutations influence SARS-CoV-2 spike binding in humans and animals

Researchers at the University of Wisconsin–Madison aimed to better understand how SARS-CoV-2 interacts with various mammalian angiotensin-converting enzyme 2 (ACE2) receptors. This way, they can identify the factors that influence intra- and cross-species virus transmission.

18 Mar 2021

Engineering immunogens to focus immune response to SARS-CoV-2

Researchers have designed constructs by adding more glycans and adding the receptor-binding motif from related sarbecoviruses to focus the immune response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding motif. Such immunogens could potentially also neutralize other variants and coronaviruses.

18 Mar 2021

Identifying druggable targets on an essential SARS-CoV-2 protein

In a research paper recently uploaded to the preprint server bioRxiv by Newman et al. (March 15th, 2021) the structure and role of one such protein: NSP13, is investigated, with two appealingly druggable targets being identified, possibly opening a new route towards a novel SARS-CoV-2 antiviral agent.

18 Mar 2021

Fighting SARS-CoV-2 with materials science

In a recent editorial in the journal Emergent Materials, Dr. Huseyin C. Yalcin from Qatar University Biomedical Research Center and Dr. Ajeet Kaushik from Florida Polytechnic University announce several important developments in their timely special issue entitled “Materials Science in the Battle against COVID-19”.

18 Mar 2021

Study reveals biomarkers for the prognosis of gastric adenocarcinoma

Low plasma levels of protein TGFB1 and polymorphisms in gene TGFB1 act as biomarkers for the prognosis of gastric adenocarcinoma, according to a study led by the University Complutense of Madrid.

18 Mar 2021

Study explores how CAR T immunotherapy could be used to treat solid tumors

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumors in addition to leukemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future.

18 Mar 2021

New study provides comparative analysis of twelve COVID-19 vaccines

A new study by Novateur Ventures provides a comparative analysis of twelve COVID-19 Vaccines that had initiated or announced the Phase III clinical trial stage by early November 2020.

18 Mar 2021

New technique uses cell's own recycling machinery to destroy disease-causing proteins

Scientists at the University of Wisconsin-Madison have developed a way to use a cell's own recycling machinery to destroy disease-causing proteins, a technology that could produce entirely new kinds of drugs.

18 Mar 2021

A modified protein mediates development of lung fibrosis after cadmium/carbon black exposure

The triggers and causes of a severe scarring disease of the lungs -- idiopathic pulmonary fibrosis, or IPF -- remain unclear.

18 Mar 2021

Novel cancer-fighting gene therapy enters phase I clinical trial

Researchers from the MDC and Charité have developed a new gene therapy based around a special T-cell receptor that helps the immune system effectively recognize and fight cancer cells.

18 Mar 2021

Scientists explore structure of SARS-CoV-2 receptor-binding domain with G485R mutation

Researchers at the Bio21 Institute and Department of Biochemistry and Pharmacology, The University of Melbourne, studied the structure of a SARS-CoV-2 spike receptor-binding domain (RBD) with a G485R mutation. This mutation is a residue and not directly involved in interactions with the angiotensin-converting enzyme 2 (ACE2) residues but found in the Β1´/Β2' loop region.

18 Mar 2021

New study maps SARS-CoV-2 and host protein interactions in detail

A new study has developed a systemic map detailing the mechanistic interactions and disruptions between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its host cell.

18 Mar 2021

SARS-CoV-2 variants with E484K mutation show mRNA vaccine-induced antibody evasion

A recent study found that the Pfizer-BioNTech mRNA vaccine had limited efficacy in identifying mutated receptor-binding domains (RBDs) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein similar to the B.1.351 and P.1 variants.

18 Mar 2021

How resistant is the SARS-CoV-2 Brazilian variant to antibodies?

Researchers based at the University of Oxford, UK, have shown that the P.1 Brazilian variant of SARS-CoV-2 is less resistant to natural or vaccine acquired antibody responses than the B.1.351, South African, variant, despite sharing convergent mutations.

18 Mar 2021